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A b s t r a c t
The reasons for the publication of current expert consensus statement after 4 years from the previous one are: the growing 
number of evidence on the benefits of the use of single-pill combinations (SPCs) in hypertension (also with concomitant 
dyslipidaemia), the extension of indications for their use in the hypertension management algorithm and the emergence in 
recent years after the publication of Polish Society of Hypertension experts’ position statement in 2013 of new types of SPCs 
available to doctors in Poland, including triple-drug combinations of antihypertensives and the so-called “hybrids” SPCs 
containing not only antihypertensive drugs but also statins. 
The current position statement of experts summarizes the progress of knowledge and practical application of SPCs of antihy-
pertensives in Poland. It seems that there will be a long gap in the introduction of new classes of antihypertensive drugs. The 
only noticeable progress in the pharmacotherapy of hypertension in the last 15 years, which may explain some increase in 
the effectiveness of blood pressure control in patients, is more common use of SPCs of antihypertensive drugs. Analysis of 
European Society of Hypertension (ESH) experts’ lectures during this year’s ESH 2017 Annual Meeting in Milan suggests that 
the next edition of the 2018 ESH Guidelines may include major changes in the antihypertensive therapy algorithm, suggesting 
the need for initiation of pharmacologic treatment with combination therapy, i.e. SPCs, in most patients with hypertension. 
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Combination of an angiotensin converting enzyme (ACE) inhibitor + calcium antagonist should be considered optimal in 
patients with high and very high cardiovascular risk. Undoubtedly, the position of this combination is due to the ACCOM-
PLISH trial in which such SPCs werefound to be more effective in reducing cardiovascular risk than SPCs composed of an 
ACE-inhibitor + thiazide diuretic. As a result of gradually increasing popularity of combined drugs, further SPCs that meet 
the criteria for optimal combination of antihypertensive drugs emerged in Poland between 2012 and 2017. Two of them 
provided the possibility of using SPCs in patients who do not need or should not use renin–angiotensin–aldosterone inhibitors. 
An interesting alternative is the SPC which contains antihypertensive agents along with other drugs used in cardiovascular 
prevention: statins and acetylsalicylic acid. This direction in the evolution of pharmacotherapy of hypertension is approaching 
the concept of “polypill”. In the opinion of the authors, the use of SPCs in antihypertensive therapy will increase in Poland, 
which may contribute to further improvement of pressure control in our country. At present, almost all useful anti-hypertensive 
agents are available in the form of two-drug SPCs. The combination of a sartan with beta-blocker for hypertensive patients with 
cardiac hypertrophy who do not tolerate ACE inhibitors and a “hybrid” SPCs of an ACE inhibitor + statin are still expected. 
Three-drug combinations: ACE inhibitor + beta-blocker + calcium antagonist, for patients with hypertension and coronary 
artery disease requiring intensive therapy, and ACE inhibitor + beta-blocker + statin, which will enable SPCs therapy for 
most patients, would also be useful.
Key words: single-pill combinations, fixed-dose combination
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Hypertension is a major modifiable risk factor for cardiovas-
cular diseases (ischaemic heart disease, stroke, heart failure 
and ischaemic artery disease of the lower limbs) and the most 
epidemiologically significant cause of death in the world. At 
the same time, the prevalence of hypertension in Poland 
is constantly increasing — according to the 2002 NATPOL 
study, it was 29% of adult Polish population [1]. In the sec-
ond NATPOL study, the proportion of hypertensive patients 
increased to 32% [2] and in the WOBASZ II study in 2014 it 
reached 43% [3].
Large clinical trials indicate that effective blood pres-
sure control is the most important condition for attaining the 
primary goal of treating hypertension, i.e., reduction of the 
mortality and incidence of cardiovascular events. Although 
the efficacy of blood pressure control in Poland has increased 
— according to the NATPOL programme, from 12% to 26% 
between 2002 and 2011 [2], and according to the WOBASZ 
programme, from 10% to 23% between 2005 and 2014 [3], it 
is still low, which is mainly attributed to poor awareness of the 
presence and need for treatment of hypertension. However, 
as indicated by the data from above-mentioned programmes, 
even among treated patients less than 50% attain target blood 
pressure. The basic causes of low efficacy of hypertension 
control are patients’ poor adherence to lifestyle changes and 
low compliance with pharmacotherapy, the therapeutic inertia 
of doctors and lack of significant progress in the development 
of new antihypertensive agents in recent years. The progress 
in the efficacy of treatment of hypertension in Poland, which 
is observed despite these circumstances, is likely to be as-
sociated with the emergence of the single-pill combinations 
(SPCs) that improve compliance, reduce therapeutic inertia, 
and are equivalent to progress in the pharmacotherapy of 
hypertension. 
The use of combination drugs in Poland has risen stead-
ily, reaching a total of 12% of all antihypertensives in 2016, 
which is still unsatisfactory because the European average 
is twice as high. Hence the efforts of the Polish Society of 
Hypertension (PSH) to improve the situation, expressed as 
highlighting the role of the SPCs in the 2011 and 2015 PSH 
Guidelines [4, 5], as well as cyclical publication of PSH experts’ 
position statement on the role of combination drugs (issued 
in 2009 and 2013) [6, 7]. 
The reasons for the publication of current expert con-
sensus statement after 4 years are: the growing number of 
evidence on the benefits of SPC use in hypertension (also 
with concomitant dyslipidaemia), the extension of indications 
for their use in the hypertension management algorithm and 
the emergence in recent years, after the publication of PSH 
experts’ position statement in 2013, of new types of single-pill 
combinations available to doctors in Poland, including tri-
ple-drug combinations of antihypertensives and the so-called 
“hybrids” SPC containing not only antihypertensive drugs but 
also statins or acetylsalicylic acid (ASA). The current position 
statement of experts summarizes the progress of knowledge 
and practical application of single-pill combinations of anti-
hypertensives in our country.
SINGLE-PILL COMBINATION OF  
ANTIHYPERTENSIVE AGENTS AS  
AN EXPRESSION OF PROGRESS IN THE  
PHARMACOTHERAPY OF HYPERTENSION
The history of progress in the pharmacotherapy of hy-
pertension can be divided into several stages (Table 1). 
After the invention in 1940s and 1950s of a number of sym-
patholytic drugs that were characterised by frequent adverse 
effects and were only an alternative to sympathectomy for 
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severe malignant hypertension, the first modern antihyper-
tensive agent was chlorothiazide — a diuretic introduced in 
1957. Then, after 10 years, there was the “golden decade” 
of antihypertensive pharmacotherapy, when almost all major 
drug classes were invented, and the greatest achievement of 
that time was the first inhibitor of angiotensin-converting en-
zyme (ACE), captopril, developed in 1977. Another important 
group of drugs were sartans which were introduced several 
years later. The last group of clinically relevant antihyperten-
sive drugs, used since 2000, are the renin inhibitors, but they 
were not more advanced than the most popular groups of 
renin-angiotensin-aldosterone (RAA) system inhibitors and 
are practically not used in Poland. 
A review of scientific literature indicates that in the 21st 
century, despite many attempts, no new class of antihyperten-
sive drugs that could improve the efficacy of blood pressure 
control (e.g., endothelin receptor antagonists, neutral endo-
peptidase inhibitors) has been introduced. Current research 
into new drug classes (including AT2 receptor agonists, amin-
opeptidase A and N inhibitors, prorenin inhibitors, natriuretic 
peptide receptor agonists, dopamine inhibitors, intestinal ion 
exchanger inhibitors Na+/H+, group -SH donors opening 
potassium channels in vascular smooth muscles, direct cGMP 
stimulators), although some are promising, do not provide 
a real basis for expecting significant clinical progress in the 
field of antihypertensive pharmacotherapy.
In conclusion, it seems that there will be a long pause in 
the introduction of new classes of antihypertensive drugs, as 
the development of multiple drugs is in the I/II phase trials, 
without the guarantee of performing a large clinical trial meet-
ing the evidence-based medicine (EBM) criteria (multicentre, 
prospective, comparative, randomised, double-blind, includ-
ing a suitably large population, with an assessment of the drug 
effect on both blood pressure values and morbidity/mortality 
due to the assessed disease entity); however, some of them 
have identified other stronger indications (heart failure, pul-
monary hypertension, diabetes mellitus). For example, a new 
hybrid drug that affects both RAA and enzymes responsible 
for the degradation of natriuretic peptide (valsartan/sacubitril) 
has been approved for the treatment of heart failure, despite 
clear hypotensive effect.
The only noticeable progress in the pharmacotherapy of 
hypertension in the last 15 years, which may explain some 
increase in the effectiveness of blood pressure control in 
patients, is more common use of single-pill combinations 
of antihypertensive drugs. It is worth recalling that the SPCs 
have a long history in hypertensiology, but in the 1960s the 
preparations were based on drugs that are no longer used (e.g. 
reserpine + binazine, reserpine + dihydralazine). Hence, 
after a period of relatively low interest in SPCs, the introduc-
tion of modern SPCs at the beginning of the 21st century, the 
consolidation and extension of indications for combination 
therapy in the guidelines of scientific societies, the growing 
number of combination types, and the studies that have shown 
the benefits of SPCs have made these preparations increas-
ingly popular among doctors. In Poland, in 2 years, the use 
of single-pill combination drugs increased by 50%, reaching 
in 2016 a total of 12% of all antihypertensive drugs. In this 
respect, further progress can be anticipated, as this is half that 
of the European average. 
ADVANTAGES OF COMBINATION  
ANTIHYPERTENSIVE DRUGS
The balance of benefits and disadvantages of SPCs in antihy-
pertensive therapy, which we presented in the 2009 expert 
position statement, is still valid in terms of benefits, which are 
after 8 years supported by more robust evidence; however, 
the disadvantages have been largely eliminated (Table 2). 
Table 1. History of progress of antihypertensive  
pharmacotherapy
1937 Reserpine
1947 Hydralazine Surgical treatment  
(sympathectomy)1947 Ganglion-blocking drugs
1955 Guanethidine
1957 Thiazide diuretics (chlorothiazide)
1967 Spironolactone
1968 Methyldopa
1973 Beta-blockers (propranolol)
1970s Alpha 2 receptor agonists (clonidine)
1970s Nod-dihydropyridine calcium antagonists (verapamil)
1975 Alpha-blockers (prazosin)
1975 Dihydropyridine calcium antagonists (nifedipine)
1977 ACE inhibitors (captopril)
1990 Sartans (losartan)
2000 Renin inhibitors (aliskiren)
After 2000 Modern combination drugs
Table 2. Pros and cons for using antihypertensive single-pill 
combinations
Pros Cons
Fewer tablets to be taken
Lower doses of component drugs
Better tolerance
Comfort
Improved adherence
Lower costs
Rapidly achieved blood pressure 
control
Lower dosing flexibilit
Problems with  
establishing the source  
of adverse effects
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The postulated at that time low dose flexibility was due to 
the fact that many SPC formulations had only one form. The 
SPCs were previously called FDCs — Fixed-Dose Combina-
tions; the later name could suggest definite and unchangeable 
doses of components of the combination drug, which, with the 
current variety of potency of specific SPCs, is no longer true. 
Currently, most SPCs have from three (two-drug SPCs) to six 
(three-drug SPCs) forms, thereby allowing for a modification 
of therapy, which is especially important, considering current 
recommendation that in the event of insufficient blood pres-
sure control the dose be increased after 2–4 weeks. Potential 
difficulties in determining the source of adverse effects are 
limited to possible allergic reactions, as the typical adverse 
effects of main groups of antihypertensive drugs are different 
and easily identifiable.
Some of the benefits of SPC (lower doses of individual 
components and, therefore, better tolerance; more rapid 
pressure control) result from the advantages of combination 
therapy. It should be reminded that the meta-analysis of 
the results of 42 controlled studies in 11,000 hypertensive 
patients showed that the additional antihypertensive effect 
of the combination of drugs from two different groups is 
almost five times greater than that of doubling the dose of 
a single drug [8]. This observation performed 8 years ago is of 
particular importance in the context of the analysis of results 
of the VALUE trial, indicating a significantly greater reduction 
in cardiovascular risk in those patients who have achieved 
blood pressure control within the first 6 months of treatment 
[9]. The advantages of combination therapy and SPC in terms 
of efficacy can now be significantly better utilised due to the 
considerable extension of therapeutic indications in 2011 PSH 
guidelines and 2013 ESH Guidelines [4, 5, 10]. 
Additional benefits, directly associated with the SPC, 
i.e. the smaller number of tablets and the convenience of 
dosage, translate into the most important advantage of the 
SPC which is improving the patient’s adherence in terms of 
both compliance and persistence. In this respect, the most 
referential study is meta-analysis of Gupta et al. [11], which 
included 15 studies and more than 32,000 patients, demon-
strating that compared to control group, patients taking SPCs 
were characterised by better compliance (odds ratio [OR] 
1.21, 95% confidence interval [CI] 1.03–1.43) and a strong 
trend towards improved persistence (OR 1.54; CI 0.95–2.49), 
which translated into a greater reduction in blood pressure 
(4.1/3.1 mm Hg) and a trend toward more frequent nor-
malisation of blood pressure (OR 1.30; CI 0.98–1.71). Many 
overviews and subsequent systematic reviews, meta-analyses 
and retrospective cohort studies, although not all, confirm 
the benefits of SPC in treating hypertension with respect to 
improving patients’ compliance [12–14]. The Italian cohort 
study by Corrao et al. [15], which included 209,650 patients, 
found that initiation of SPC therapy resulted in significantly 
greater reductions in cardiovascular (11%), coronary (8%) and 
cerebrovascular (12%) risks compared with monotherapy and 
stepped therapy. In the ACCOMPLISH study, switching from 
the current treatment with separate antihypertensive agents 
to SPC containing an ACE inhibitor resulted in a two-fold 
increase in the efficacy of blood pressure control from about 
40% to about 80%, regardless of the type of SPC used [16].
It should be assumed that the use of SPC may also con-
tribute to the reduction of the second serious cause of low 
effectiveness of antihypertensive therapy, i.e. the therapeutic 
inertia of doctors, by reducing the concerns associated with 
concurrent use of several antihypertensive drugs.
INDICATIONS FOR THE USE OF COMBINATIONS 
OF ANTIHYPERTENSIVE DRUGS AND THEIR 
ROLE IN ESH AND PSH GUIDELINES
The increased importance of combination antihypertensive 
drugs is largely a consequence of the fact that scientific 
societies have extended the indications for the use of poly-
therapy in their guidelines. The basic premises of the use 
of combination antihypertensive therapy have been stated 
in the 2007 ESH/ESC 2007 guidelines and included too 
low proportion of patients achieving blood pressure goal 
with monotherapy. It was suggested that in case of failure 
of monotherapy, the treatment should be changed to com-
bination therapy and that preferred combinations of two 
drugs should be used as first-line therapy in stage 2 and 
3 hypertension and/or in patients with high cardiovascular 
risk [17]. In both cases, the 2007 ESH Guidelines assumed 
the possibility of using the SPC. The next ESH Guidelines, 
issued in 2013 [10], strengthened this trend, by allowing in 
the treatment algorithm the possibility of early switching to 
combination therapy in patients with stage 1 hypertension 
and including a recommendation to consider initiating of 
antihypertensive treatment with two-drug combination in 
stage 2 hypertension and the possibility of preferring com-
bination therapy with SPC. However, both of these recom-
mendations were of a relatively low class IIb, due to the 
level of evidence B, resulting from only one, according to 
opinion of the ESH experts, available relevant study — the 
Canadian STITCH trial. It is worth recalling that in this study, 
the treatment based on the single-pill combination therapy 
provided better control of blood pressure and faster achieve-
ment of target values than the treatment algorithm starting 
with monotherapy (65% vs. 53% with mean blood pressure 
reduction of 23/10 vs. 18/8 mm Hg) [18].
In the opinion of the authors, recommendations for the 
use of SPC in the ESH Guidelines are too conservative. This 
document does not include data from the STRATHE study 
[19], in which initiation of antihypertensive treatment with 
a SPC was superior to stepped therapy (from monotherapy to 
combination therapy) or sequential therapy (switching from 
ineffective drug to another one). Moreover, it is important to 
realise that the greatest advantage of SPCs over conventional 
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combination therapy with separate agents, that is improved 
compliance that may translate into increased efficacy, is im-
possible to assess in accurately performed classic EBM studies 
which are based on the assumption of good compliance and 
thus overstate it. Paradoxically, less appreciated retrospective 
studies are free of this limitation.
It seems that a strong recommendation of SPC preference 
in combination therapy should be taken on a common sense 
basis. Since combination drugs provide better patient compli-
ance, this has to translate into better antihypertensive efficacy, 
as currently the low effectiveness of blood pressure control 
observed in studies such as the NATPOL study is explained 
by poor patient cooperation with the physician, although this 
statement is not confirmed by any direct evidence. 
This direction for the positioning of SPCs has been 
adopted by the authors of PSH Guidelines and its latest ver-
sion issued in 2015 includes following recommendation: “In 
combination therapy, it is worthwhile to use single-pill com-
bination of two drugs, which allows for increasing treatment 
efficacy (STITCH and ACCOMPLISH), simplifying treatment 
regimen and increasing patients adherence (meta-analysis)” 
[5]. Already in the document published in 2011 [4], consid-
eration was given in treatment algorithm to the possibility of 
early switching to combination therapy in patients with stage 
1 hypertension, and in 2015 PSH Guidelines this method 
of intensifying therapy is preferred. In addition, the antihy-
pertensive treatment algorithm indicates that in each case of 
combination therapy a SPC should be preferred. A novelty 
resulting from ongoing but not yet completed clinical tri-
als was the prediction in 2015 PSH Guidelines that “in the 
future, combination therapy with antihypertensive agents in 
doses smaller than the standard ones, available in two- and 
three-drug combinations may be an alternative for initiating 
the therapy in patients with stage 1 and 2/3 hypertension re-
spectively”. At present, such a new indication for starting the 
treatment in stage 1 hypertension with a single-pill combina-
tion of drugs in sub-standard doses has become a fact, besides 
the SPC containing perindopril and indapamide, also for the 
combination of perindopril and amlodipine (3.5 mg/2.5 mg) 
after the publication of two clinical trials documenting the 
superiority of such SPC therapy over monotherapy with 
perindopril or amlodipine in typical doses [20] and over 
stepped therapy (sartan –> sartan/amlodipine) in terms of 
the time to achieving target blood pressure and the percent-
age of well-controlled patients [21]. This new indication will 
probably be included in 2018 PSH Guidelines, but it can be 
recommended already.
Analysis of ESH experts’ lectures (Volpe, Williams) during 
this year’s ESH 2017 Annual Meeting in Milan suggests [22] that 
the next edition of the 2018 ESH Guidelines may include major 
changes in the antihypertensive therapy algorithm, suggesting 
the need for initiation of pharmacologic treatment with com-
bination therapy, i.e. SPC, in most patients with hypertension.
BASIC SPCs AND INDIVIDUALISATION  
OF THEIR USE
Currently there are eight types of two-drug SPCs and two types 
of three-drug SPCs, excluding the combinations of diuretics with 
different sites of action within the nephron and hybrids which will 
be discussed separately. These numbers have doubled over the 
past 6 years, which is another proof of the intense development 
of this concept of treating hypertension. Types of combination 
drugs introduced by the pharmaceutical companies are not ac-
cidental and almost perfectly reflect the principles of combining 
antihypertensive drugs. All available types of SPC, except thiazide 
diuretics + beta-blockers, are combinations of drugs considered 
in 2015 PSH Guidelines as optimal due to complementary 
mechanisms of action, proven cardiovascular risk reduction (as 
combination therapy or SPC), or unambiguous preference for 
both components in specific groups of patients. 
Of these, ACE inhibitor + calcium antagonist, ACE inhibi-
tor + thiazide/thiazide-like diuretic, sartan + thiazide diuretic 
and sartan + calcium antagonist should be considered as 
the key combinations used in the treatment of hypertension, 
which is supported by some arguments. The experience of 
Polish doctors in the use of these four combinations is the 
greatest because all of these drugs have been available for 
more than 10 years, meet the condition of presence of RAA 
inhibitor in combination, and three of them (Figure 1) have 
the largest body of evidence that they reduce cardiovascu-
lar risk in combination and provide a natural direction for 
initiation and/or intensification of therapy in uncomplicated 
arterial hypertension. It is worth noting that all of these are 
three-drug combinations including a RAA inhibitor + calcium 
antagonist + thiazide/thiazide-like diuretic, which are consid-
ered to be obligatory in intensive treatment of uncomplicated 
arterial hypertension.
Among these four combinations, some preferences for 
their use can be outlined depending on patient’s global car-
diovascular risk and metabolic status. These preferences are 
based on the observations described in 2015 PSH Guidelines 
suggesting that ACE inhibitors, due to additional bradykinin 
mechanism, are the most effective among all RAA inhibitors 
in reducing cardiovascular risk, which has been shown in 
recent meta-analyses [23–25], while thiazide-like diuretics 
due to additional vasodilatative mechanism are less likely to 
cause metabolic abnormalities, are more effective in reducing 
blood pressure and delaying organ damage, and have greater 
body of EBM evidence for cardiovascular risk reduction in 
combination with ACE inhibitors. The proportion of successful 
large clinical trials is different for these four combinations [10]. 
Combination of an ACE inhibitor + calcium antagonist 
should be considered optimal in patients with high and very 
high cardiovascular risk. Undoubtedly, the position of this 
combination is due to the ACCOMPLISH trial in which such 
SPC was found to be more effective in reducing cardiovas-
cular risk than SPC composed of an ACE-inhibitor + thiazide 
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diuretic [16]. Additionally, many clinical studies have shown 
the organ-protective effect of such combination. Currently, 
four combinations of this type are available in Poland: perin-
dopril + amlodipine, ramipril + amlodipine, lisinopril + am-
lodipine and relatively recent enalapril + lerkanidipine. The 
strongest clinical evidence for the reduction of “hard” end-
points is available for the combination of perindopril + am-
lodipine due to the ASCOT study, the first large head-to-head 
trial in patients with uncomplicated arterial hypertension in 
which significant reduction in cardiovascular mortality was 
observed in patients receiving amlodipine + perindopril com-
pared to those treated with a beta-blocker + thiazide diuretic 
combination [26]. In addition, CAFÉ study, accompanying 
ASCOT study, showed a more effective reduction in central 
pressure. Moreover, the combination of perindopril + am-
lodipine in substandard doses, as one of very few along with 
the combination of perindopril and indapamide in the lowest 
doses, has the previously described indication for initiation of 
therapy in stage 1 hypertension [27].
For all these combinations, with good EBM data for its 
components, available are studies that document their blood 
pressure-lowering and organ-protective efficacy: perindo-
pril + amlodipine (STRONG) [28], ramipril + amlodipine 
(ATAR) [29], lisinopril + amlodipine (ALFESS, HAMLET) [30, 
31], enalapril + lerkanidipine (FELT) [32].
Interestingly for practical reasons, the four listed com-
binations of ACE inhibitors + calcium antagonists can be 
differentiated due to the principles of chronotherapy of 
hypertension. Two ACE inhibitors, perindopril and lisinopril, 
are characterised by a 24-hour antihypertensive effect similar 
to amlodipine, so when used in combination, they provide 
24-hour blood pressure control after morning administra-
tion in dippers. Ramipril and enalapril, on the other hand, 
have shorter time of action, and even in combination with 
a long-acting calcium antagonist evening dosing may be use-
ful in non-dippers.
Particularly important and frequently prescribed are SPCs 
containing an ACE inhibitor + thiazide/thiazide-like diuret-
ics which are used to enhance the antihypertensive effect of 
an ACE inhibitor by inducing hypovolaemia and increasing 
plasma renin activity by thiazide/thiazide-like diuretic, rather 
in patients with higher cardiovascular risk. Virtually all ACE 
inhibitors are available in combination with thiazide diuretic 
— hydrochlorothiazide. The only one currently available 
combination of an ACE inhibitor with preferred thiazide-like 
diuretic is SPC containing perindopril + indapamide, which 
is distinguished in the 2015 PSH guidelines because of 
three major clinical trials (ADVANCE, HYVET, PROGRESS) 
documenting the benefits of this combination in patients with 
concomitant diabetes mellitus, very elderly and with a history 
of stroke [33–35]. These are special indications reserved for 
this combination. 
A combination that is most commonly used in Poland 
— sartan + thiazide diuretic — has similar synergistic antihy-
pertensive effect but should be used in patients with moderate 
and low cardiovascular risk. This combination is characterised 
by very good tolerance and it was evaluated in large clinical 
EBM trials demonstrating a reduction in cardiovascular risk 
in patients with left ventricular hypertrophy (LIFE) [36] and in 
patients with moderate cardiovascular risk (VALUE) [37]. As 
with ACE inhibitors, practically for all available sartans there 
are SPCs with hydrochlorothiazide, but two of them (valsar-
tan + hydrochlorothiazide and telmisartan + hydrochloro-
thiazide) are particularly useful because of the popularity of 
these sartans. Unfortunately, no combination of a sartan with 
preferred thiazide-like diuretic is available in Poland, although 
in some countries such preparations are already available 
(combinations of sartans with chlortalidone).
The last primary SPC, a sartan + calcium antagonist, is less 
commonly used due to the lack of large EBM studies. Howev-
er, combinations of valsartan with amlodipine (EX-FAST) [38] 
and telmisartan with amlodipine (TEAMSTA) [39] are worth 
Figure 1. Percentage of positive outcome studies with basic combinations of antihypertensive drugs
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remembering, especially in patients with metabolic disorders, 
due to a very good tolerance, favourable metabolic profile 
and documented antihypertensive effect. These combinations 
include components with proven efficacy in large clinical tri-
als of patients with hypertension and high cardiovascular risk 
or coronary artery disease. In controlled clinical trials with 
single-pill combination of telmisartan and amlodipine, target 
blood pressure was achieved in 80% of patients with stage 1 or 
2 hypertension and 50% of patients with stage 3 hypertension, 
with low incidence of adverse events.
Another manifestation of advances in the treatment 
with combined antihypertensive drugs is the appearance 
of three-drug SPCs in Poland, which offers the possibility 
of intensifying the therapy using one tablet also in patients 
with higher baseline blood pressure values, including stage 
3 hypertension. Both types of these combinations: ACE in-
hibitor + dihydropyridine calcium antagonist + thiazide-like 
diuretic (the only available SPC is perindopril + indapam-
ide + amlodipine) and older one, sartan + dihydropyridine 
calcium antagonist + thiazide diuretic (the only available SPC 
is valsartan + hydrochlothiazide + amlodipine) meet the crite-
rion for optimum combination in uncomplicated hypertension. 
It is important to note that only for three-drug combination of 
perindopril + indapamide + amlodipine there are available 
analyses of randomized trials demonstrating the benefits in 
terms of cardiovascular risk reduction (ADVANCE) [40] and 
increase in the antihypertensive effect (PIANIST) [41]. This 
combination has a unique pharmacokinetic profile resulting 
from different peak concentrations of its components, which 
provides a stable daily antihypertensive effect without sudden 
blood pressure drop in first hours after administration, despite 
the activity of three drugs.
NEW SPCs FOR SPECIFIC USE
As a result of gradually increasing popularity of combined 
drugs, further SPCs that meet the criteria for optimal com-
bination of antihypertensive drugs emerged in Poland in 
2012–2017. Two of them provided the possibility of using SPC 
in patients who do not need or should not use RAA inhibitors.
The combination of a beta-blocker + calcium antagonist 
(the only available SPC is bisoprolol + amlodipine) is particu-
larly applicable in uncomplicated hypertension in younger 
patients requiring combination therapy, especially in women 
of childbearing potential. The advantage of this SPC, in ad-
dition to the antihypertensive effectiveness (BETAMLO) [42], 
is good tolerance resulting from the opposite chronotropic 
effect of both components, with a tendency to decrease heart 
rate [43]. The latter feature makes SPC containing bisopro-
lol + amlodipine also suitable for use in patients who have 
cardiac complications and are prone to tachycardia, basically 
in combination with an ACE inhibitor, since the three-drug 
SPC of an ACE inhibitor + dihydropyridine calcium antago-
nist + beta-blocker is not yet available. 
Another optimal combination of thiazide-like diuret-
ics + calcium antagonists (the only one available SPC is 
indapamide + amlodipine) fills the gap in the possibility of 
using SPC in uncomplicated hypertension in elderly patients 
requiring combination therapy, since both components are 
recognised in the ESH and PSH Guidelines as preferred 
drugs. The antihypertensive efficacy of this combination 
has been demonstrated in the EFFICIENT study [44] and, if 
intensification of treatment is necessary, it may be conveni-
ent to switch the patient to the available three-drug SPC of 
perindopril + indapamide + amlodipine.
Single-pill combination of a beta-blocker + thiazide 
diuretic (the only available SPC is nebivolol + hydrochloro-
thiazide) is recommended as a component of the therapy in 
patients with hypertension and heart failure rather than for 
starting antihypertensive therapy. It is worth noting, however, 
that the presence in this combination of a beta-blocker with 
vasodilative properties, nebivolol, which has more favour-
able metabolic effect, mitigates traditional objections to the 
potential disadvantageous effects of long-term use of the 
combination of a beta-blocker + thiazide diuretic on carbo-
hydrate or lipid metabolism.
The most recent combination of a beta-blocker + ACE 
inhibitor (the only one available SPC is bisoprolol + perindo-
pril) is dedicated to patients with hypertension complicated 
with coronary heart disease, because, according to 2015 PSH 
Guidelines, in these patients, regardless of myocardial infarc-
tion history, antihypertensive therapy should be based on 
such a combination. Sub-analysis of the EUROPA study [45] 
showed that patients with stable coronary heart disease using 
perindopril with a beta-blocker had a lower risk of myocardial 
infarction and cardiovascular death compared to those using 
a beta-blocker alone. It is worth noting that the SPC containing 
bisoprolol with perindopril is the only SPC registered simultane-
ously in the three largest population therapeutic indications: 
hypertension, coronary heart disease, and heart failure.
The Pol-Focus study [46] showed that the combination of 
a beta-blocker with ACE inhibitor is most commonly used in 
two-drug therapy by Polish doctors. Therefore, from practical 
point of view, this combination may be useful in younger pa-
tients with uncomplicated hyperkinetic hypertension (bisoprolol 
component) and already present symptoms of organ damage, 
e.g. left ventricular hypertrophy (perindopril component).
“HYBRID” SPCs OF ANTIHYPERTENSIVE DRUGS 
WITH OTHER DRUGS IMPORTANT  
FOR CARDIOVASCULAR PREVENTION
An interesting alternative is the SPC which contains antihyper-
tensive agents along with other drugs used in cardiovascular 
prevention: statins and acetylsalicylic acid. This direction in the 
evolution of pharmacotherapy of hypertension is approaching 
the concept of “polypill”, but the difference consist in that it 
assumes drug dosage control based on blood pressure and 
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plasma cholesterol measurements in individual patients, while 
the “polypill” concept is targeted at societies of poor organisa-
tion of healthcare system and assumes the improvement of 
cardiovascular risk at population level through the widespread 
use of the “polypill” containing low-doses of preventive drugs 
by all individuals above a certain global cardiovascular risk 
(e.g., based on age) without further detailed control and 
dosage modification.
Combinations of antihypertensive drugs with statins aim 
to simultaneously improve the two most important pharmaco-
logically modifiable cardiovascular risk factors: hypertension 
and hypercholesterolaemia. These factors additively increase 
global cardiovascular risk, and the number of people who are 
at the same time at risk of hypertension and hypercholes-
terolaemia is estimated in Poland at several million people. 
The first SPC of this type, available in Poland for many years, 
is the combination of atorvastatin + amlodipine. However, 
this SPC was characterised by too low doses of atorvastatin 
available in this combination (10 mg or 20 mg). The rela-
tively low popularity of this combination was also caused by 
the fact that statin in primary prevention was indicated only 
in patients with hypertension and high cardiovascular risk, 
whereas it is patients with lower risk who are treated with 
monotherapy alone. The recently introduced combination of 
rosuvastatin + amlodipine is more likely to succeed because, 
after announcing the results of the JUPITER study [47], we 
know that statin therapy can be recommended in patients 
with hypertension and lower cardiovascular risk. In addition, 
doctors’ habits regarding the evening use of statins are progres-
sively changing with respect to modern statins, atorvastatin 
and rosuvastatin, whose efficacy in lowering LDL-cholesterol 
is the same irrespective of the time of administration. The 
decisive factor should be patients’ compliance, which can be 
improved by SPCs. Moreover, new recommendations for lipid 
lowering therapy and further lowering of the target values of 
LDL-cholesterol will in practice favour more potent statins, 
such as rosuvastatin (20 mg or higher dose) or atorvastatin at 
higher doses (40 mg or 80 mg).
Very interesting “hybrid” SPC, which became available 
in Poland at the beginning of 2017, is a three-drug combina-
tion of a statin + ACE inhibitor + calcium antagonist (the 
only available SPC is atorvastatin + perindopril + amlodi-
pine). Strong evidence for clinical benefits of this combina-
tion was provided by the lipid shoulder of the ASCOT study 
[48] in which atorvastatin caused three-fold higher reduc-
tion of the risk of myocardial infarction in patients taking 
amlodipine and perindopril than in those receiving atenolol 
and bendroflumethiazide, with comparable blood pressure 
and LDL-cholesterol control, suggesting the synergistic ef-
fects of atorvastatin, perindopril and amlodipine. Similarly, 
significant relative reduction (33% vs. 2%) in cardiovascular 
mortality was observed in the atorvastatin group only in 
patients taking amlodipine + perindopril. Compared with 
the previous ones, this SPC meets the criteria for a combina-
tion of antihypertensive drugs and therefore may be used as 
one tablet formulation in patients with stage 2 hypertension 
with moderate to high cardiovascular risk and concomitant 
metabolic and/or diabetic complications. Similar three-drug 
formulations containing a calcium antagonist, an ACE in-
hibitor or sartan, and atorvastatin or rosuvastatin will be 
introduced into the Polish pharmaceutical market soon. 
The most recent interesting “hybrid” SPC is the combina-
tion of a statin + sartan (the only available SPC is rosuvasta-
tin + valsartan) that can be successfully used in stage 1 hyper-
tension with concomitant hypercholesterolaemia, especially in 
patients with metabolic syndrome, because it contains valsartan 
(NAVIGATOR) [49]. The combined use of sartans and statins 
also has a beneficial effect on reducing the risk of cardiovas-
cular events (by approximately 40%) in patients with multiple 
comorbidities [50]. The NAVIGATOR study evaluating the 
effect of SPC of rosuvastatin + valsartan versus monotherapy 
on blood pressure and LDL-cholesterol levels has shown that 
the use of this SPC is associated with better control of both risk 
factors which can be explained by better adherence to medical 
recommendations (by 34%) and greater therapeutic persistence.
Another option for “hybrid” SPC therapy is the combina-
tion of a beta-blocker + ASA acid (the only available SPC is 
bisoprolol + ASA) for patients with ischaemic heart disease 
or heart failure regardless of the presence of hypertension. 
It has been argued to justify the use of this SPC that patients 
after myocardial infarction are likely to arbitrary discontinue 
ASA, while they are most persistent with beta-blocker therapy. 
So far, this SPC has not become popular because of doctors’ 
habits related to the evening administration of ASA. It is dic-
tated by the belief that ASA inhibits more effectively platelet 
activation when administered in the evening. 
FUTURE DEVELOPMENT OF  
ANTIHYPERTENSIVE THERAPY WITH SPCs
In the opinion of the authors, the use of SPCs in antihyperten-
sive therapy will increase in Poland, which may contribute to 
further improve of pressure control in our country. At present, 
almost all useful anti-hypertensive agents are available in the 
form of two-drug SPCs. The combination of a sartan with 
beta-blocker for hypertensive patients with cardiac hyper-
trophy who do not tolerate ACE inhibitors and a “hybrid” 
SPC of an ACE inhibitor + statin are still expected. Three-
-drug combinations: ACE inhibitor + beta-blocker + calcium 
antagonist, for patients with hypertension and coronary artery 
disease requiring intensive therapy, and ACE inhibitor + beta-
-blocker + statin, which will enable single-pill combination 
therapy for most patients, would also be useful. 
However, in order for these favourable trends to gain 
momentum, two conditions must be met both by the group 
of experts who develop the guidelines for treatment of hy-
pertension and representatives of authorities responsible for 
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registration process and approving indications for the use of 
specific drugs, e.g. SPCs. 
The first of these conditions is a change in the philosophy 
of the antihypertensive treatment algorithm consisting in the 
assumption that pharmacotherapy of hypertension be initiated 
with combination therapy, with preference for SPC for most 
patients, and that identified should be those patients who are 
likely to benefit from monotherapy (stage 1 hypertension with 
low global cardiovascular risk). As mentioned above, analysis 
of ESH experts’ lectures (Volpe, Williams) at this year’s ESH 
2017 Congress in Milan suggests that such changes are con-
sidered [22] and that new PSH recommendations will also 
follow this direction (Figure 2).
It is more difficult to fulfil the second condition because 
it requires a change of approach to the indications for the use 
of SPC by officials, taking into account expert opinions. Cur-
rently, only two combination drugs, perindopril + amlodi-
pine in substandard doses, as described above, and some 
formulations of perindopril + indapamide at lower doses 
are indicated for initiation of antihypertensive therapy. Most 
SPCs have so-called “add-on indication”, which means the 
requirement of lack of control with one component alone, or 
so-called “substitute indication”, that means the requirement 
of previous adequate control of blood pressure on both com-
ponents of SPC. It would be logical to give all SPC indications 
for the initiation of antihypertensive therapy in patients with 
stage 2 hypertension (i.e., according to the recommendations 
of the scientific societies), since there is nothing to prevent 
a doctor from prescribing any two antihypertensive drugs in 
combination as starting therapy. Such a solution is supported 
by not only by medical but also economic reasons.
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Serdecznie zapraszamy na
22. Sympozjum Sekcji Rehabilitacji Kardiologicznej i Fizjologii Wysiłku
Polskiego Towarzystwa Kardiologicznego,
które odbędzie się w dniach 15–17 marca 2018 roku, 
w Jachrance koło Warszawy w Hotelu Warszawianka.
Tematem przewodnim konferencji będzie „Niewydolność serca — opieka kompleksowa”.
Bogaty program naukowy i szeroki wachlarz prezentowanych zagadnień czynią z Sympozjum  
najważniejsze wydarzenie naukowe dla wszystkich, którzy interesują się rehabilitacją kardiologiczną w Polsce. 
Szczegółowy program i rejestracja na stronie: http://rehabilitacja2018.ptkardio.pl
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